Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer

Breast Cancer Research and Treatment

Volumn 134, Issue 3, 2012, Pages 943-955

  Wang, Neng ^a   Wang, Zhi Yu ^a   Mo, Sui Lin ^b   Loo, Tjing Yung ^a   Wang, Dong Mei ^b   Luo, Hai Bin ^b   Yang, De Po ^b   Chen, Yu Ling ^c   Shen, Jian Gang ^a   Chen, Jian Ping ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anti angiogenesis; Breast cancer; Ellagic acid; Molecular docking; VEGF VEGFR2

Indexed keywords

ELLAGIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MITOSIS INHIBITION; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ELLAGIC ACID; ENZYME ACTIVATION; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868195812     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1977-9     Document Type: Article

References (39)

1. Coughlin SS, Ekwueme DU (2009) Breast cancer as a global health concern. Cancer Epidemiol 33:315-318
2. Miller KD (2004) Recent translational research: antiangiogenic therapy for breast cancer-where do we stand? Breast Cancer Res 6:128-132
3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
4. Khosravi Shahi P, Soria Lovelle A, Pérez Manga G (2009) Tumoral angiogenesis and breast cancer. Clin Transl Oncol 11:138-142
5. Senger DR, Van De Water L, Brown LF et al (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324
6. Kurebayashi J, Otsuki T, Kunisue H et al (1999) Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 90:977-981
7. Tortora G, Melisi D, Ciardiello F (2004) Angiogenesis: a target for cancer therapy. Curr Pharm Des 10:11-26
8. Hoeben A, Landuyt B, Highley MS et al (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549-580
9. Ferrara N, Gerber HP, Le Couter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
10. Guo S, Colbert LS, Fuller M et al (2010) Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 1806:108-121
11. Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of signaling molecules. Nature 441:457-462
12. McTigue MA, Wickersham JA, Pinko C et al (1999) Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7:319-330
13. Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303:1800-1805
14. Lu J, Zhang K, Nam S, Anderson RA et al (2010) Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR-2 kinase and downstream signaling. Carcinogenesis 31:481-488
15. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795
16. Wahle KW, Brown I, Rotondo D et al (2011) Plant phenolics in the prevention and treatment of cancer. Adv Exp Med Biol 698:36-51
17. Athar M, Back JH, Kopelovich L et al (2009) Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 486:95-102
18. Gacche RN, Shegokar HD, Gond DS et al (2011) Evaluation of selected flavonoids as antiangiogenic, anticancer, and radical scavenging agents: an experimental and in silico analysis. Cell Biochem Biophys. doi:10.1007/s12013- 011-9251-z
19. Han DH, Lee MJ, Kim JH (2006) Antioxidant and apoptosisinducing activities of ellagic acid. Anticancer Res 26:3601-3606
20. Priyadarsini KI, Khopde SM, Kumar SS, Mohan H (2002) Free radical studies of ellagic acid, a natural phenolic antioxidant. J Agric Food Chem 50:2200-2206
21. Labrecque L, Lamy S, Chapus A et al (2005) Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietaryderived phenolic compound. Carcinogenesis 26:821-826
22. Lee KH, Choi HR, Kim CH (2005) Anti-angiogenic effect of the seed extract of Benincasa hispida Cogniaux. J Ethnopharmacol 97:509-513
23. Losso JN, Bansode RR, Trappey A 2nd et al (2004) In vitro antiproliferative activities of ellagic acid. J Nutr Biochem 15:672-678
24. Shyu KG, Tsai SC, Wang BW et al (2004) Saikosaponin C induces endothelial cells growth, migration and capillary tube formation. Life Sci 76:813-826
25. Auerbach R, Lewis R, Shinners B et al (2003) Angiogenesis assays: a critical overview. Clin Chem 49:32-40
26. Wen W, Lu J, Zhang K et al (2008) Grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway. Cancer Prev Res (Phila) 1:554-561
27. Zhang S, Cao Z, Tian H et al (2011) SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 17:4439-4450
28. Colavitti R, Pani G, Bedogni B et al (2002) Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277:3101-3108
29. Price JE, Polyzos A, Zhang RD et al (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50:717-721
30. Wang D, Stockard CR, Harkins L et al (2008) Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 83:179-189
31. Harris PA, Cheung M, Hunter RN 3rd et al (2005) Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEG-FR-2 kinase inhibitors. J Med Chem 48:1610-1619
32. Sekiguchi Y, Nakaniwa T, Kinoshita T et al (2009) Structural insight into human CK2a in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett 19:2920-2923
33. Fox SB, Generali DG, Harris AL (2007) Breast tumour angiogenesis. Breast Cancer Res 9:216
34. Paz K, Zhu Z (2005) Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front Biosci 10:1415-1439
35. Gingras D, Lamy S, Béliveau R (2000) Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem J 348:273-280
36. Jung MH, Lee SH, Ahn EM et al (2009) Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 30:655-661
37. Chung BH, Lee JJ, Kim JD et al (2010) Angiogenic activity of sesamin through the activation of multiple signal pathways. Biochem Biophys Res Commun 391:254-260
38. Gabriele B, Rolf B, Gerald M et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744
39. Shinkaruk S, Bayle M, Laïn G et al (2003) Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 3:95-117